» Articles » PMID: 31222077

Innovative Mouse Model Mimicking Human-like Features of Spinal Cord Injury: Efficacy of Docosahexaenoic Acid on Acute and Chronic Phases

Overview
Journal Sci Rep
Specialty Science
Date 2019 Jun 22
PMID 31222077
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Traumatic spinal cord injury has dramatic consequences and a huge social impact. We propose a new mouse model of spinal trauma that induces a complete paralysis of hindlimbs, still observable 30 days after injury. The contusion, performed without laminectomy and deriving from the pressure exerted directly on the bone, mimics more closely many features of spinal injury in humans. Spinal cord was injured at thoracic level 10 (T10) in adult anesthetized female CD1 mice, mounted on stereotaxic apparatus and connected to a precision impactor device. Following severe injury, we evaluated motor and sensory functions, and histological/morphological features of spinal tissue at different time points. Moreover, we studied the effects of early and subchronic administration of Docosahexaenoic acid, investigating functional responses, structural changes proximal and distal to the lesion in primary and secondary injury phases, proteome modulation in injured spinal cord. Docosahexaenoic acid was able i) to restore behavioural responses and ii) to induce pro-regenerative effects and neuroprotective action against demyelination, apoptosis and neuroinflammation. Considering the urgent health challenge represented by spinal injury, this new and reliable mouse model together with the positive effects of docosahexaenoic acid provide important translational implications for promising therapeutic approaches for spinal cord injuries.

Citing Articles

Integrated proteomic and metabolomic profiling of lymph after trauma-induced hypercoagulopathy and antithrombotic therapy.

Zheng Y, Wang P, Cong L, Shi Q, Zhao Y, Wang Y Thromb J. 2024; 22(1):59.

PMID: 38987792 PMC: 11234664. DOI: 10.1186/s12959-024-00634-3.


Sex-specific adipose tissue's dynamic role in metabolic and inflammatory response following peripheral nerve injury.

Vacca V, Rossi C, Pieroni L, De Angelis F, Giacovazzo G, Cicalini I iScience. 2023; 26(10):107914.

PMID: 37817933 PMC: 10561049. DOI: 10.1016/j.isci.2023.107914.


Xeomin, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury.

Mastrorilli V, De Angelis F, Vacca V, Pavone F, Luvisetto S, Marinelli S Toxins (Basel). 2023; 15(4).

PMID: 37104185 PMC: 10142820. DOI: 10.3390/toxins15040248.


Glial-Neuronal Interactions in Pathogenesis and Treatment of Spinal Cord Injury.

Lukacova N, Kisucka A, Kiss Bimbova K, Bacova M, Ileninova M, Kuruc T Int J Mol Sci. 2021; 22(24).

PMID: 34948371 PMC: 8708227. DOI: 10.3390/ijms222413577.


Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties.

Luca R, Assenza M, Maiullari F, Pieroni L, Maiullari S, Federici G Cell Death Dis. 2021; 12(6):558.

PMID: 34052831 PMC: 8164635. DOI: 10.1038/s41419-021-03828-z.


References
1.
Benton R, Maddie M, Gruenthal M, Hagg T, Whittemore S . Neutralizing endogenous VEGF following traumatic spinal cord injury modulates microvascular plasticity but not tissue sparing or functional recovery. Curr Neurovasc Res. 2009; 6(2):124-31. PMC: 2813492. DOI: 10.2174/156720209788185678. View

2.
Cadotte D, Fehlings M . Spinal cord injury: a systematic review of current treatment options. Clin Orthop Relat Res. 2010; 469(3):732-41. PMC: 3032846. DOI: 10.1007/s11999-010-1674-0. View

3.
Figueroa J, Cordero K, Baldeosingh K, Torrado A, Walker R, Miranda J . Docosahexaenoic acid pretreatment confers protection and functional improvements after acute spinal cord injury in adult rats. J Neurotrauma. 2011; 29(3):551-66. PMC: 3278822. DOI: 10.1089/neu.2011.2141. View

4.
Niquet J, Baldwin R, Allen S, Fujikawa D, Wasterlain C . Hypoxic neuronal necrosis: protein synthesis-independent activation of a cell death program. Proc Natl Acad Sci U S A. 2003; 100(5):2825-30. PMC: 151425. DOI: 10.1073/pnas.0530113100. View

5.
Bazan N . The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol. 2006; 26(4-6):901-13. PMC: 11520625. DOI: 10.1007/s10571-006-9064-6. View